These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 24135727

  • 1. Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
    Bondada L, Rondla R, Pradere U, Liu P, Li C, Bobeck D, McBrayer T, Tharnish P, Courcambeck J, Halfon P, Whitaker T, Amblard F, Coats SJ, Schinazi RF.
    Bioorg Med Chem Lett; 2013 Dec 01; 23(23):6325-30. PubMed ID: 24135727
    [Abstract] [Full Text] [Related]

  • 2. Phosphorous acid analogs of novel P2-P4 macrocycles as inhibitors of HCV-NS3 protease.
    Pompei M, Francesco ME, Koch U, Liverton NJ, Summa V.
    Bioorg Med Chem Lett; 2009 May 01; 19(9):2574-8. PubMed ID: 19328685
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
    Lampa A, Ehrenberg AE, Gustafsson SS, Vema A, Kerblom E, Lindeberg G, Karlén A, Danielson UH, Sandström A.
    Bioorg Med Chem; 2010 Jul 15; 18(14):5413-24. PubMed ID: 20541424
    [Abstract] [Full Text] [Related]

  • 6. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
    Llinàs-Brunet M, Bailey MD, Bolger G, Brochu C, Faucher AM, Ferland JM, Garneau M, Ghiro E, Gorys V, Grand-Maître C, Halmos T, Lapeyre-Paquette N, Liard F, Poirier M, Rhéaume M, Tsantrizos YS, Lamarre D.
    J Med Chem; 2004 Mar 25; 47(7):1605-8. PubMed ID: 15027850
    [Abstract] [Full Text] [Related]

  • 7. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG, Chen KX, Shih NY, Piwinski JJ.
    Acc Chem Res; 2008 Jan 25; 41(1):50-9. PubMed ID: 18193821
    [Abstract] [Full Text] [Related]

  • 8. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM, Ali MAM, El-Gendy BEM, Dandash SS, Issac Y, Saad R, Azab MM, Mohamed MR.
    Curr Pharm Des; 2018 Jan 25; 24(37):4484-4491. PubMed ID: 30501598
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Computational Modelling in Studies for Hepatitis C Virus (HCV) NS3 Protease.
    Mukhametov A.
    Curr Top Med Chem; 2016 Jan 25; 16(12):1351-61. PubMed ID: 26585936
    [Abstract] [Full Text] [Related]

  • 12. Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
    Venkatraman S, Velazquez F, Wu W, Blackman M, Madison V, Njoroge FG.
    Bioorg Med Chem Lett; 2010 Apr 01; 20(7):2151-5. PubMed ID: 20226659
    [Abstract] [Full Text] [Related]

  • 13. Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones.
    Ortqvist P, Gising J, Ehrenberg AE, Vema A, Borg A, Karlén A, Larhed M, Danielson UH, Sandström A.
    Bioorg Med Chem; 2010 Sep 01; 18(17):6512-25. PubMed ID: 20673728
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogs.
    Bilodeau F, Bailey MD, Bhardwaj PK, Bordeleau J, Forgione P, Garneau M, Ghiro E, Gorys V, Halmos T, Jolicoeur ES, Leblanc M, Lemke CT, Naud J, O'Meara J, White PW, Llinàs-Brunet M.
    Bioorg Med Chem Lett; 2013 Jul 15; 23(14):4267-71. PubMed ID: 23735741
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S, Njoroge FG, Girijavallabhan VM, Madison VS, Yao NH, Prongay AJ, Butkiewicz N, Pichardo J.
    J Med Chem; 2005 Aug 11; 48(16):5088-91. PubMed ID: 16078825
    [Abstract] [Full Text] [Related]

  • 17. Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy.
    Ndjomou J, Corby MJ, Sweeney NL, Hanson AM, Aydin C, Ali A, Schiffer CA, Li K, Frankowski KJ, Schoenen FJ, Frick DN.
    ACS Chem Biol; 2015 Aug 21; 10(8):1887-96. PubMed ID: 25961497
    [Abstract] [Full Text] [Related]

  • 18. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY, Lu CS, Lin TH.
    J Mol Graph Model; 2008 Apr 21; 26(7):1131-44. PubMed ID: 18024210
    [Abstract] [Full Text] [Related]

  • 19. Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.
    Ortqvist P, Peterson SD, Kerblom E, Gossas T, Sabnis YA, Fransson R, Lindeberg G, Helena Danielson U, Karlén A, Sandström A.
    Bioorg Med Chem; 2007 Feb 01; 15(3):1448-74. PubMed ID: 17113777
    [Abstract] [Full Text] [Related]

  • 20. Peptide inhibitors of hepatitis C virus NS3 protease.
    Portal-Núñez S, González-Navarro CJ, García-Delgado M, Vizmanos JL, Lasarte JJ, Borrás-Cuesta F.
    Antivir Chem Chemother; 2003 Sep 01; 14(5):225-33. PubMed ID: 14694985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.